PTSD Drug Candidate Granted Breakthrough Therapy Designation

Preliminary data from a Phase 2 study in PTSD favored TNX-102 SL over currently available treatments
Preliminary data from a Phase 2 study in PTSD favored TNX-102 SL over currently available treatments

Tonix announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of posttraumatic stress disorder (PTSD)

The designation was supported by preliminary data from the 12-week randomized, double-blind, placebo-controlled Phase 2 AtEase study in military-related PTSD that favored treatment with TNX-102 SL over currently available treatments. 

Related Articles

TNX-102 SL, a sublingual formulation of cyclobenzaprine, is a serotonin-2A, alpha-1 adrenergic, and histamine H1 antagonist under development for PTSD to provide broad spectrum improvement by targeting sleep and the stress response.

The Phase 3 HONOR study is anticipated to begin enrollment in the first quarter of 2017 pending an FDA agreement on the study's design and interim analysis plan.

For more information visit TonixPharma.com.

Loading links....